IMPDH2
Basic information
Region (hg38): 3:49024325-49029447
Links
Phenotypes
GenCC
Source:
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
IMPDH2 enzyme activity, variation in | AD | Pharmacogenomic | Variants may be involved in response to treatment with medications such as mycophenolate mofetil in individuals who have undergone transplants | Biochemical | 17496727 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the IMPDH2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 17 | 19 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 1 | 1 | 2 | |||
non coding | 2 | |||||
Total | 0 | 2 | 19 | 1 | 1 |
Variants in IMPDH2
This is a list of pathogenic ClinVar variants found in the IMPDH2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-49024489-A-G | Uncertain significance (Nov 27, 2023) | |||
3-49024514-C-T | not specified | Uncertain significance (Aug 14, 2023) | ||
3-49024547-C-G | Uncertain significance (Jun 27, 2023) | |||
3-49024547-CAAACTT-C | Uncertain significance (Sep 07, 2023) | |||
3-49024587-G-A | IMPDH2-related disorder | Likely benign (Sep 04, 2019) | ||
3-49024741-T-C | not specified | Uncertain significance (Sep 14, 2022) | ||
3-49024793-G-C | Uncertain significance (May 13, 2023) | |||
3-49025134-G-A | Uncertain significance (Dec 01, 2022) | |||
3-49025182-C-T | Uncertain significance (Apr 01, 2023) | |||
3-49025232-G-T | Uncertain significance (Sep 24, 2022) | |||
3-49026365-C-T | not specified | Uncertain significance (Aug 04, 2023) | ||
3-49026549-A-G | not specified | Uncertain significance (Dec 28, 2023) | ||
3-49026677-A-G | IMPDH2-related disorder | Benign (Jan 21, 2021) | ||
3-49026719-G-A | IMPDH2 enzyme activity, variation in | Affects (Apr 01, 2007) | ||
3-49026756-A-C | not specified | Uncertain significance (Oct 04, 2022) | ||
3-49026757-A-C | Uncertain significance (Aug 11, 2022) | |||
3-49026791-C-G | Uncertain significance (Jun 24, 2021) | |||
3-49026793-T-C | Likely pathogenic (Feb 24, 2022) | |||
3-49026866-CATT-C | Uncertain significance (Jun 18, 2023) | |||
3-49026960-C-G | Uncertain significance (May 15, 2019) | |||
3-49026965-T-C | not specified | Uncertain significance (Oct 12, 2022) | ||
3-49026986-T-C | Uncertain significance (Apr 24, 2024) | |||
3-49027029-C-T | Uncertain significance (Nov 11, 2023) | |||
3-49027038-T-C | not specified | Uncertain significance (Jun 03, 2022) | ||
3-49027052-G-A | IMPDH2-related disorder | Likely benign (Feb 14, 2020) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
IMPDH2 | protein_coding | protein_coding | ENST00000326739 | 14 | 5084 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000436 | 0.991 | 125690 | 0 | 58 | 125748 | 0.000231 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.50 | 176 | 297 | 0.592 | 0.0000173 | 3367 |
Missense in Polyphen | 46 | 114.97 | 0.40011 | 1301 | ||
Synonymous | -0.931 | 123 | 111 | 1.11 | 0.00000597 | 1021 |
Loss of Function | 2.35 | 13 | 25.9 | 0.502 | 0.00000129 | 307 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000517 | 0.000454 |
Ashkenazi Jewish | 0.000103 | 0.0000992 |
East Asian | 0.000549 | 0.000544 |
Finnish | 0.000198 | 0.000185 |
European (Non-Finnish) | 0.000150 | 0.000149 |
Middle Eastern | 0.000549 | 0.000544 |
South Asian | 0.000392 | 0.000392 |
Other | 0.000489 | 0.000489 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate- limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in the development of malignancy and the growth progression of some tumors.;
- Pathway
- Drug metabolism - other enzymes - Homo sapiens (human);Purine metabolism - Homo sapiens (human);Mycophenolic acid Pathway, Pharmacokinetics;Mycophenolic acid Pathway, Pharmacokinetics/Pharmacodynamics;Mycophenolic Acid Metabolism Pathway;Neutrophil degranulation;Metabolism of nucleotides;urate biosynthesis/inosine 5,-phosphate degradation;purine nucleotides degradation;Innate Immune System;Immune System;Metabolism;Nucleobase biosynthesis;Purine nucleotides nucleosides metabolism;superpathway of purine nucleotide salvage;Purine ribonucleoside monophosphate biosynthesis;guanosine nucleotides <i>de novo</i> biosynthesis;guanosine ribonucleotides <i>de novo</i> biosynthesis;purine nucleotides <i>de novo</i> biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.394
Intolerance Scores
- loftool
- 0.581
- rvis_EVS
- -0.65
- rvis_percentile_EVS
- 16.36
Haploinsufficiency Scores
- pHI
- 0.965
- hipred
- Y
- hipred_score
- 0.701
- ghis
- 0.610
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.975
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Impdh2
- Phenotype
- immune system phenotype; cellular phenotype; hematopoietic system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span);
Zebrafish Information Network
- Gene name
- impdh2
- Affected structure
- whole organism
- Phenotype tag
- abnormal
- Phenotype quality
- decreased length
Gene ontology
- Biological process
- GMP biosynthetic process;GTP biosynthetic process;circadian rhythm;purine ribonucleoside monophosphate biosynthetic process;neutrophil degranulation;lymphocyte proliferation;protein homotetramerization;oxidation-reduction process;retina development in camera-type eye;cellular response to interleukin-4
- Cellular component
- extracellular region;nucleus;cytoplasm;peroxisomal membrane;cytosol;membrane;secretory granule lumen;extracellular exosome;ficolin-1-rich granule lumen
- Molecular function
- nucleotide binding;DNA binding;RNA binding;IMP dehydrogenase activity;protein binding;metal ion binding